Curated News
By: NewsRamp Editorial Staff
June 01, 2026
Nightfood’s TechForce Deploys LIM-E Robot in Pharma Lab
TLDR
- Nightfood Holdings' expansion into pharma automation via TechForce Robotics opens new revenue streams and competitive edge in life sciences.
- TechForce's LIM-E robot completed Phase 1 objectives under a joint development agreement with Oncotelic, validating its AI platform for lab automation.
- Automating lab tasks with robots like LIM-E accelerates drug development and improves safety, making healthcare more efficient and accessible.
- A robot originally designed for hospitality now autonomously supports pharmaceutical labs, showcasing AI's surprising versatility across industries.
Impact - Why it Matters
This deployment is important because it demonstrates the cross-industry potential of AI-enhanced robotics, moving from hospitality to life sciences. For investors, it opens up new revenue streams for Nightfood Holdings through its RaaS model in a high-growth market. For the pharmaceutical industry, it could lead to increased efficiency and reduced costs in laboratory workflows, potentially accelerating drug development and manufacturing.
Summary
Nightfood Holdings (OTCQB: NGTF) has announced a significant milestone through its subsidiary TechForce Robotics, which successfully completed Phase 1 objectives under a joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC). The highlight of this achievement is the initial deployment of LIM-E, an autonomous laboratory support robot, marking TechForce’s first expansion into pharmaceutical and laboratory automation. This deployment validates the adaptability of TechForce’s AI-enhanced robotics platform, demonstrating its capability beyond traditional hospitality and service-industry applications into life sciences and pharmaceutical environments. The completion of these objectives fulfills the initial operational goals established under the April 2026 collaboration agreement, providing valuable operational data and workflow insights to guide future automation initiatives.
TechForce Robotics, a subsidiary focused on AI-enhanced automation, plans to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows, and other automation applications. Nightfood views healthcare, life sciences, and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service (RaaS) platform. The company’s RaaS model combines advanced hardware, intelligent software, and scalable infrastructure to support growth across multiple industries. Meanwhile, Oncotelic Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. This collaboration could enhance operational efficiency in drug development and manufacturing processes.
The full press release is available at https://ibn.fm/RFkfL. For more information about Oncotelic, visit www.oncotelic.com. To learn more about Nightfood Holdings, visit www.nightfoodholdings.com. TechForce Robotics’ website is www.techforcerobotics.com. The latest news on NGTF is available at http://ibn.fm/NGTF.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nightfood’s TechForce Deploys LIM-E Robot in Pharma Lab
